UNITED STATES SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 [  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934

 

For the quarterly period ended March 31, 2012

 

Commission File No. 0-22179

 

 

GUIDED THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware (State or other jurisdiction of incorporation or organization)

58-2029543 (I.R.S. Employer Identification No.)

 

 

5835 Peachtree Corners East, Suite D Norcross, Georgia  30092 (Address of principal executive offices) (Zip Code)

 

(770) 242-8723

(Registrant’s telephone number, including area code)     

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes [  ] No [ X ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes [ X ] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-12 of the Exchange Act (Check one):

 

Large Accelerated filer _____ Accelerated filer ____ Non-accelerated filer_____ Smaller Reporting Company  [X]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. 

Yes [   ]  No [X]

 

As of May 7, 2012, the registrant had outstanding 52,946,645 shares of Common Stock.

 

 

 

 

 

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

 

INDEX

 

 

Part I.  Financial Information	3
Item 1.     Financial Statements	3
Condensed Consolidated Balance Sheets (Unaudited) -
March 31, 2012 and December 31, 2011	3
Condensed  Consolidated Statements of Operations (Unaudited)
Three months ended March 31, 2012 and 2011	4
Condensed Consolidated Statements of Cash Flows (Unaudited)
Three months ended March 31, 2012 and 2011	5
Notes to Condensed Financial Statements (Unaudited)	6
Item 2.      Management's Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.     Quantitative and Qualitative Disclosures About Market Risk	15
Item 4.     Controls and Procedures	15
Part II. Other Information	16
Item 1.     Legal Proceedings	16
Item 1A.  Risk Factors	16
Item 5.     Other Information	16
Item 6.    Exhibits	16
Signatures	17

 

 

 

 

 

  

PART I - FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited in Thousands Except Share Data)

 

  

		AS OF
ASSETS		March 31, 2012				December 31, 2011
CURRENT ASSETS:
Cash and cash equivalents		$	1,004			$	2,200
Accounts receivable, net of allowance for doubtful accounts of $4 and $20 at March 31, 2012 and December 31, 2011			38				117
Inventory, net of reserves of $64  at March 31, 2012 and December 31, 2011			608				520
Other current assets			45				54
Total current assets			1,695				2,891
Property and equipment, net			1,088				1,033
Other assets			302				386
Total noncurrent assets			1,390				1,419
TOTAL ASSETS		$	3,085			$	4,310
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Short-term notes payable		$	—			$	30
Current portion of long term debt			24				25
Notes payable – past due			375				362
Accounts payable			863				1,102
Accrued liabilities			687				757
Deferred revenue			228				453
Total current liabilities			2,177				2,729
Long-term debt payable, less current portion			—				4
TOTAL LIABILITIES			2,177				2,733
COMMITMENTS & CONTINGENCIES (Note 4)
STOCKHOLDERS’ EQUITY:
Common stock, $.001 Par value; 100,000 shares authorized, 52,697 and 52,211 shares issued and outstanding as of March, 31 2012    and December 31, 2011, respectively			53				52
Additional paid-in capital			86,957				86,614
Treasury stock, at cost			(104	)			(104	)
Accumulated deficit			(86,102	)			(85,089	)
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS’ EQUITY			804				1,473
Non-controlling interest			104				104
TOTAL STOCKHOLDERS’ EQUITY			908				1,577
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	3,085			$	4,310
The accompanying notes are an integral part of these condensed consolidated financial statements.

   

 

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in Thousands Except Share Data)

 

 

		2012				2011
REVENUE:
Contract and grant revenue		$	718			$	767
COSTS AND EXPENSES:
Research and development			714				696
Sales and marketing			70				49
General and administrative			930				762
Total			1,714				1,507
Operating loss			(996	)			(740	)
OTHER INCOME			—				37
INTEREST EXPENSE			(17	)			(23	)
LOSS  BEFORE INCOME TAXES			(1,013	)			(726	)
PROVISION FOR INCOME TAXES			—				—
NET LOSS		$	(1,013	)		$	(726	)
BASIC AND DILUTED NET LOSS PER SHARE		$	(0.02	)		$	(0.02	)
WEIGHTED AVERAGE SHARES OUTSTANDING			52,471				47,851

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in Thousands)
		FOR THE THREE MONTHS ENDED MARCH 31,
		2012				2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(1,013	)		$	(726	)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt recovery			(16	)			—
Depreciation and amortization			75				4
Stock based compensation			198				142
Conversion of interest to principal			—				23
Gain on debt renegotiated Changes in operating assets and liabilities:			—				(23	)
Inventory			(88	)			—
Accounts receivable			96				(58	)
Other current assets			8				6
Accounts payable			(239	)			36
Deferred revenue			(225	)			(253	)
Accrued liabilities			(70	)			(108	)
Other assets			84				(62	)
Total adjustments			(177	)			(293	)
Net cash used in operating activities			(1,190	)			(1,019	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to capitalized software costs			—				(53	)
Additions to fixed assets			(130	)			(16	)
Net cash used in investing activities			(130	)			(69	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from options and warrants exercised			146				175
Payments on notes and loan payables			(22	)			(48	)
Net cash provided by financing activities			124				127
NET CHANGE IN CASH AND CASH EQUIVALENTS			(1,196	)			(961	)
CASH AND CASH EQUIVALENTS, beginning of year			2,200				3,268
CASH AND CASH EQUIVALENTS, end of period		$	1,004			$	2,307
SUPPLEMENTAL SCHEDULE OF:
Cash paid for:
Interest		$	5			$	1
NONCASH INVESTING AND FINANCING ACTIVITIES:
Conversion of accounts  payable into common stock		$	—			$	27
Settlement of debt upon conversion of warrants		$	—			$	42

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

 

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

 

1.   BASIS OF PRESENTATION

  

The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X by Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its majority owned subsidiary InterScan, Inc., (“Interscan”) (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”. Accordingly, they do not include all information and footnotes required by GAAP for complete financial statements. These statements reflect adjustments, all of which are of a normal, recurring nature, and which are, in the opinion of management, necessary to present fairly the Company’s financial position as of March 31, 2012, results of operations for the three months ended March 31, 2012 and 2011, and cash flows for the three months ended March 31, 2012 and 2011. The results of operations for the three months ended March 31, 2012 are not necessarily indicative of the results for a full fiscal year. Preparing financial statements requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities. Actual results could differ from those estimates. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2011.

 

The Company's prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of March 31, 2012, it had an accumulated deficit of approximately $86.1 million. Through March 31, 2012, the Company has devoted substantial resources to research and development efforts. The Company does not have significant experience in manufacturing, marketing or selling its products. The Company's development efforts may not result in commercially viable products and it may not be successful in introducing its products. Moreover, required regulatory clearances or approvals may not be obtained. The Company's products may not ever gain market acceptance and the Company may not ever achieve levels of revenue to sustain further development costs and support ongoing operations or achieve profitability. The development and commercialization of the Company's products will require substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue through the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals and conduct further research and development.

 

Going Concern

 

The Company’s financial statements have been prepared and presented on a basis assuming it will continue as a going concern.  The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern. Notwithstanding the foregoing, the Company believes it has made progress in stabilizing its financial situation by execution of multiyear contracts from Konica Minolta Opto, Inc., a subsidiary of Konica Minolta, Inc., a Japanese corporation based in Tokyo (“Konica Minolta”) and grants from the National Cancer Institute (“NCI”), while at the same time simplifying its capital structure and significantly reducing debt.

 

At March 31, 2012, the Company’s has a negative working capital of approximately $482,000 and it had stockholders’ equity of approximately $908,000, primarily due to the recurring losses. As of March 31, 2012, the Company was past due on payments due under its notes payable in the amount of approximately $375,000.

 

The Company’s capital-raising efforts are ongoing. If sufficient capital cannot be raised during the fourth quarter of 2012, the Company has plans to curtail operations by reducing discretionary spending and staffing levels, and attempting to operate by only pursuing activities for which it has external financial support, such as under its development agreement with Konica Minolta and additional NCI or other grant funding. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.

 

  

The Company could receive additional funding from Konica Minolta or other strategic partners as well as new federal grants that could bring in an additional $700,000. It also has warrants exercisable for approximately 30.8 million shares of its common stock outstanding, a substantial majority of which have an exercise price of $0.65 per share. Through March 31, 2012, exercises of these warrants have generated approximately $1.3 million and would generate a total of approximately $18.4 million in cash, assuming full exercise. Management may obtain additional funds through the private sale of preferred stock or debt securities, public and private sales of common stock, funding from collaborative arrangements, and grants, if available, and believes that such financing will be sufficient to support planned operations through the first quarter of 2013.

 

Assuming the Company receives FDA approval for its LuViva cervical cancer detection device in 2012, the Company currently anticipates an early 2013 product launch in the United States. Product launch outside the United States is expected in the second half of 2012, but cannot be assured it will be able to launch on these timetables, or at all.

 

2.   SIGNIFICANT ACCOUNTING POLICIES

 

The Company’s significant accounting policies were set forth in the audited financial statements and notes thereto for the year ended December 31, 2011 included in its annual report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”).

 

Accounting Standards Updates

 

Newly effective accounting standards updates and those not effective until after March 31, 2012, are not expected to have a significant effect on the Company’s financial position or results of operations.

 

Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.

 

Concentration of Credit Risk

 

The Company, from time to time during the periods covered by these consolidated financial statements, may have bank balances in excess of their insured limits. Management has deemed this as a normal business risk.

 

Property and equipment

 

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are depreciated at the shorter of the useful life of the asset or the remaining lease term. Depreciation expense is included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred.

 

Inventory Valuation

 

All inventories are stated at lower of cost or market, with cost determined substantially on a “first-in, first-out” basis.  Selling, general, and administrative expenses are not inventoried, but are charged to expense when purchased. At March 31, 2012 and December 31, 2011our inventories are as follows:

 

			March 31, 2012				December 31, 2012
Raw materials		$	540,479			$	433,007
Work in process			129,148				149,069
Finished goods			1,960				1,960
Inventory reserve			(64,036	)			(64,036	)
Total		$	607,551			$	520,000

 

 

Revenues

 

Majority of the Company’s revenues were from the Konica Minolta and NCI. Revenue from these customers totaled approximately $631,000 or 91% and approximately $757,000 or 99% of total revenue for the three months ended March 31, 2012 and 2011, respectively.

  

 

Accounts Receivable

 

The Company performs periodic credit evaluations of its customers’ financial condition and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable.

 

Revenue Recognition

 

The Company recognizes revenue from contracts on a straight line basis, over the terms of the contract. We recognize revenue from grants based on the grant agreement, at the time the expenses are incurred. Revenue from the sale of the Company’s products is recognized upon shipment of such products to its customers. 

 

Deferred Revenue

We defer payments received as revenue until earned based on the related contracts on a straight line basis, over the terms of the contract.

Stock Option Plan

The Company measures the cost of employees services received in exchange for equity awards, including stock options, based on the grant date fair value of the awards. The cost will be recognized as compensation expense over the vesting period of the awards.

Warrants

The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants issued to non-employees based on the fair value at the date of issue. The fair value of the warrants at date of issuance is estimated using the Black-Scholes Model.

Other Income

Other income consists of a contract with Konica Minolta for approximately $10,000 per month for reimbursement of contractual expenses. The related expenses are netted against the reimbursement and the differential is booked as other income. For the three months ended March 31, 2012 other income of approximately $30,000 were classified as revenue and for the same period in 2011, such amount of approximately $30,000 were classified as other income.

 3.    STOCK-BASED COMPENSATION

 

The Company records compensation expense related to options granted to non-employees based on the fair value of the award.

 

Compensation cost is recorded as earned for all unvested stock options outstanding at the beginning of the first year based upon the grant date fair value estimates, and for compensation cost for all share-based payments granted or modified subsequently, based on fair value estimates.

 

For the quarter ended March 31, 2012, stock-based compensation for options attributable to employees, officers and directors was approximately $198,000 and has been included in the Company's first quarter 2012 statement of operations.  Compensation costs for stock options, which vest over time, are recognized over the vesting period. As of March 31, 2012, the Company had approximately $1.9 million of unrecognized compensation cost related to granted stock options, to be recognized over the remaining vesting period of approximately three years.

 

The Company has a 1995 stock option plan (the “Plan”) approved by its stockholders for officers, directors and key employees of the Company and consultants to the Company.  Participants are eligible to receive incentive and/or nonqualified stock options.  The aggregate number of shares that may be granted under the Plan is 8,255,219 shares.  The Plan is administered by the compensation committee of the board of directors.  The selection of participants, grant of options, determination of price and other conditions relating to the exercise of options are determined by the compensation committee of the board of directors and administered in accordance with the Plan.

 

Both incentive stock options and non-qualified options granted to employees, officers and directors under the Plan are exercisable for a period of up to 10 years from the date of grant, at an exercise price that is not less than the fair market value of the common stock on the date of the grant.  The options typically vest in installments of 1/48 of the options outstanding every month.

 

 

A summary of the Company’s activity under the Plan as of March 31, 2012 and changes during the three months then ended is as follows:

 

		Shares				Weighted average exercise price				Weighted average remaining contractual (years)				Aggregate intrinsic value (thousands)
Outstanding, January 1, 2012			6,862,167			$	0.70
Granted			2,500			$	0.70
Exercised / Expired			(100,000	)		$	3.33
Outstanding, March 31, 2012			6,764,667			$	0.66				7.40			$	1,539
Vested and exercisable, March 31, 2012			4,910,835			$	0.44				6.61			$	2,217

 

The Company estimates the fair value of stock options using a Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the expected term, expected volatility of the Company’s stock, the risk free interest rate, option forfeiture rates, and dividends, if any. The expected term of the options is based upon the historical term until exercise or expiration of all granted options. The expected volatility is derived from the historical volatility of the Company’s stock on the OTCBB market for a period that matches the expected term of the option. The risk-free interest rate is the constant maturity rate published by the U.S. Federal Reserve Board that corresponds to the expected term of the option.

 

4.     LITIGATION AND CLAIMS

 

As previously reported, in October 2010, the Company received a letter from an attorney representing Dolores M. Maloof and James E. Funderburke, two stockholders of the Company (together, the “Claimants”), asserting, among other things, that an August 2005 Warrant Agreement entered into by the Company and the Claimants (the “2005 Agreement”) had been modified by a subsequent agreement. While the Company disputed the Claimants’ assertion that an agreement modifying the 2005 Agreement had been reached, the Company determined to negotiate with the Claimants with the goal of terminating the 2005 Agreement and the rights granted thereunder to the Claimants. The 2005 Agreement, among other terms, provided for the Company to pay to the Claimants 7.5% of all net proceeds from any license or sale of the Company’s cervical cancer detection technology, without limitation.

Upon completion of negotiations with the Claimants, the Company entered into an Agreement and Release, on August 30, 2011 (the “Agreement”), by which the Claimants agreed to terminate all of their rights under the 2005 Agreement and release all claims. Accordingly, under the Agreement, the 2005 Agreement and all rights of the Claimants thereunder, including the right to receive 7.5% of proceeds from the sale or license of the Company’s cervical cancer technology, were canceled. In exchange, the Company agreed to issue warrants to the Claimants to purchase an aggregate of 2.6 million shares of the Company’s common stock at an exercise price of $0.01 per share (the “Warrants”), to pay certain royalties related to the sale of disposables in conjunction with the Company’s cervical cancer detection technology and to make certain additional payments related to non-ordinary course asset sales or a sale of the Company by merger, with such royalties and related payments subject to certain “caps” limiting their amounts. During 2011, the Company had issued the 2.6 million warrants and recorded approximately $3.6 million of warrant expenses relating to the settlement. There was no expense relating to this settlement in the three months ended March 31, 2012 and 2011.

 

The Warrants were issued in September 2011, are immediately exercisable and will expire on March 1, 2013. The shares underlying the Warrants are subject to a Registration Rights Agreement, dated August 30, 2011 (the “Registration Rights Agreement”), which obligates the Company, within 60 days, to register the shares issuable upon exercise of the Warrants for resale by the Claimants under the Securities Act of 1933, as amended. The royalties payable pursuant to the Agreement to the Claimants consist of a 2% royalty on gross revenues generated from the sale of disposables (only) used in conjunction with the Company’s cervical cancer detection technology. The cumulative royalty payable is capped at $7.2 million, and may not, together with the additional payments due in conjunction with certain non-ordinary course disposition of assets or a merger of the Company, exceed $12 million. The royalties are payable until the earlier of the sale of the Company by merger and the sale or exclusive license of all or substantially all of the Company’s cervical cancer detection technology. The Agreement further provides that, in the event of one or more non-ordinary course asset sales by the Company, or a sale of the Company by merger, the Claimants will be entitled to an aggregate of 3% of the proceeds therefrom (net of any direct and customary transaction expenses), provided that the aggregate payment due under this provision is capped at the lesser of $9.5 million and the amount by which $12.0 million exceeds the cumulative amount of all payments previously paid to the Claimants in royalties or by reason of prior non-ordinary course asset sales.

 

From time to time, the Company may be involved in various other legal proceedings and claims arising in the ordinary course of business. Management believes that the disposition of these additional matters which may occur, individually or in the aggregate, is not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular period.

 

As of March 31, 2012 and December 31, 2011, there was no accrual recorded for any potential losses related to pending litigation.

 

5.     STOCKHOLDERS' EQUITY

 

Common Stock

 

The Company has authorized 100 million shares of common stock with $0.001 par value, 52,696,519 of which were outstanding as of March 31, 2012.

 

Preferred Stock

 

The Company has authorized 5,000,000 shares of preferred stock with a $.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. The board of directors designated 525,000 shares of the preferred stock as redeemable convertible preferred stock, none of which remain outstanding.

 

Stock Options

 

Under the Plan, a total of 1,490,552 shares remained available at March 31, 2012 and 6,764,667 shares were outstanding as of that date, bringing the total number of shares subject to stock options outstanding and those remaining available for issue to 8,255,219 shares of common stock as of March 31, 2012.  The Plan allows the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options is determined by the Company’s board of directors, but incentive stock options must be granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant.

 

In January 2002, the Company assumed the Sterling Medivations 2000 Stock Option Plan, which authorizes the issuance of up to 93,765 shares of the Company’s common stock.  No options have been issued under this plan.  

 

The following table sets forth or the range of exercise prices, number of shares issuable upon exercise, weighted average exercise price, and remaining contractual lives by groups of similar price as of March 31, 2012:

 

	Options Outstanding						Options Exercisable
Range of Exercise Prices	Number of Shares	Weighted Average Exercise Price	Weighted Average Contractual Life (years)		Number of Shares			Weighted Average Price
$ 0.00 - $ 0.26	850,500	$   0.25	4.66		850,500			$   0.25
$ 0.30 - $ 0.33	2,123,500	$   0.32	6.29		2,121,417			$   0.32
$ 0.34 - $ 1.00	2,354,667	$   0.65	8.25		1,670,572			$   0.56
$ 1.10 - $ 4.46	1,436,000	$   1.47	9.29		243,347			$   1.39
Total	6,764,667	$   0.66	7.40		4,885,836			$   0.44

 

 

 

 

 

Warrants

 

The Company has the following shares reserved for the warrants outstanding as of March 31, 2012:

 

Warrants				Exercise				Expiration
(Underlying Shares)				Price				Date
	25,705,814	(1)			$0.65				03/01/2013
	2,686,523	(2)			$0.65				07/26/2012
	2,070,000	(3)			$0.01				03/01/2013
	285,186	(4)			$1.05				11/20/2016
	6,790	(5)			$1.01				09/10/2015
	30,754,313

 

 

Warrants (Underlying Shares)   Exercise Price Expiration Date 25,705,814 (1) $0.65 03/01/2013 2,686,523 (2) $0.65 07/26/2012 2,070,000 (3) $0.01 03/01/2013 285,186 (4) $1.05 11/20/2016 6,790 (5) $1.01 09/10/2015 30,754,313

 

(1)

Consists of outstanding warrants issued in connection with various financings, but amended or originally issued on February 26, 2010 to expire on March 1, 2013. During the quarter ended March 31, 2012, warrants for 212,804 shares of common stock were exercised.

(2)

Consists of outstanding warrants issued in connection with Series A conversion on February 26, 2010 to expire on July 26, 2012.

(3)

Consists of warrants to purchase common stock at a purchase price of $0.01 per share issued in conjunction with the settlement of a claim. During the quarter ended March 31, 2012, warrants for 250,000 shares of common stock were exercised.

(4)

Consists of outstanding warrants issued in conjunction with a private placement on November 21, 2011.

(5)

Consists of outstanding warrants issued in conjunction with a private placement on September 10, 2010.

 

 

6.     LOSS PER COMMON SHARE

 

Basic net loss per share attributable to common stockholders amounts are computed by dividing the net loss plus preferred stock dividends and deemed dividends by the weighted average number of common shares outstanding during the period.

 

7.     NOTES PAYABLE

 

Loan Payable

 

At December 31, 2009, the Company maintained a line of credit in the amount of $75,000 with Pacific International Bank of Seattle, Washington. This line was converted to a 36 months straight-line amortizing loan on February 24, 2010, with monthly principal and interest payment of $2,226 per month due February 2013. Interest is charged at a rate of 7.5%. At March 31, 2012, a balance of approximately $24,000 was outstanding, which is classified as current loan payable.

 

Notes Payable – Past Due

 

At December 31, 2011, the Company was past due on two short-term notes totaling approximately $362,000 of principal and accrued interest. These notes are due on demand and interest is charged at rates ranging between 15-18 %. The principal and accrued interest balance at March 31, 2012 is approximately $375,000.

 

8.     SUBSEQUENT EVENTS

 

On April 16, 2012, the Company announced the appointment of Linda Rosenstock, M.D., M.P.H. to its Board of Directors. The addition of Dr. Rosenstock increases the size of the company’s board to seven. She will stand for election at the company’s Annual Stockholder’s Meeting scheduled for June 15, 2012.

 

On March 7, 2012 we received an email from Konica Minolta Opto indicating that the esophageal cancer program and budget was likely to be approved for the fiscal year May 1, 2012 to April 30, 2013. On April 1, 2012 the research and development arm of Konica Minolta Opto was transferred to the general R&D division of Konica Minolta Holdings. This division has not yet agreed to proceed with the program and we believe that while we have been informed that the technical review of the program has been completed successfully, continuation of the program and funding may be conditional upon additional review of the potential business opportunity and long term relationship between the Company and Konica Minolta, including the eventual structure of a licensing agreement or joint partnership. We believe that these issues will be resolved over the coming weeks, however there is no precise timetable for completion and no guarantee that the program or funding will continue under conditions acceptable to the Company.

 

 

 

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Statements in this report which express "belief," "anticipation" or "expectation," as well as other statements which are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or anticipated results, including those set forth under "Risk Factors" below and elsewhere in this report. Examples of these uncertainties and risks include, but are not limited to:

 

	·	the dependence on potential strategic partners or outside investors for funding, development assistance, clinical trials, distribution and marketing of some of our products.
	·	access to sufficient debt or equity capital to meet our operating and financial needs;
	·	the effectiveness and ultimate market acceptance of our products;

	·	whether our products in development will prove safe, feasible and effective;
	·	whether and when we or any potential strategic partners will obtain approval from the U.S FDA and corresponding foreign agencies;

	·	our need to achieve manufacturing scale-up in a timely manner, and our need to provide for the efficient manufacturing of sufficient quantities of our products;
	·	the lack of immediate alternate sources of supply for some critical components of our products;

	·	our patent and intellectual property position; and
	·	the need to fully develop the marketing, distribution, customer service and technical support and other functions critical to the success of our product lines.

 

The following discussion should be read in conjunction with our financial statements and notes thereto included elsewhere in this report.

 

OVERVIEW

 

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the development of our LuViva non-invasive cervical cancer detection device and extension of our cancer detection technology into other cancers, especially lung and esophageal. Our technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers, including cervical cancer.

 

We are a Delaware corporation, originally incorporated in 1992 under the name “SpectRx, Inc.,” and, on February 22, 2008, changed our name to Guided Therapeutics, Inc. At the same time, we renamed our majority owned subsidiary, InterScan, which originally had been incorporated as “Guided Therapeutics.”

 

Since our inception, we have raised capital through the private sale of preferred stock and debt securities, public and private sales of common stock, funding from collaborative arrangements, and grants.

 

Our prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. We have experienced operating losses since our inception and, as of March 31, 2012, we have an accumulated deficit of about $86.1 million. To date, we have engaged primarily in research and development efforts. We do not have significant experience in manufacturing, marketing or selling our products. Our development efforts may not result in commercially viable products and we may not be successful in introducing our products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. Our products may not ever gain market acceptance and we may not ever generate significant revenues or achieve profitability. The development and commercialization of our products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. We expect our operating losses to continue through at least the end of 2012 as we continue to expend substantial resources to introduce LuViva, further the development of our other products, obtain regulatory clearances or approvals, build our marketing, sales, manufacturing and finance organizations and conduct further research and development.

 

 

 

Our product revenues to date have been limited. In 2011 and 2010, the majority of our revenues were from private sales of our common stock, grants from the NCI and our collaborative arrangements with Konica Minolta. We expect that the majority of our revenue in 2012 will be derived from similar sources.

 

 

CRITICAL ACCOUNTING POLICIES

 

Our material accounting policies, which we believe are the most critical to an investors understanding of our financial results and condition, are discussed below. Because we are still early in our enterprise development, the number of these policies requiring explanation is limited. As we begin to generate increased revenue from different sources, we expect that the number of applicable policies and complexity of the judgments required will increase.

 

Currently, our policies that could require critical management judgment are in the areas of revenue recognition, reserves for accounts receivable and inventory valuation.

 

Revenue Recognition: We recognize revenue from contracts on a straight line basis, over the terms of the contract. We recognize revenue from grants based on the grant agreement, at the time the expenses are incurred. Revenue from the sale of the Company’s products is recognized upon shipment of such products to its customers. 

Valuation of Deferred Taxes: We account for income taxes in accordance with the liability method. Under the liability method, we recognize deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. We establish a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income.

Valuation of Equity Instruments Granted To Employee, Service Providers and Investors: On the date of issuance, the instruments are recorded at their fair value as determined using the Black-Scholes valuation model. See Note 3 to the consolidated financial statements accompanying this report for the assumptions used in the Black-Scholes valuation.

Stock Option Plan: The Company measures the cost of employees services received in exchange for equity awards, including stock options, based on the grant date fair value of the awards. The cost will be recognized as compensation expense over the vesting period of the awards.

 

Warrants: The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants issued to non-employees based on the fair value at the date of issue. The fair value of the warrants at date of issuance is estimated using the Black-Scholes Model.

 

Allowance for Inventory Valuation: We estimate losses from obsolete and damaged inventories quarterly and revise our reserves as a result.

 

Allowance for Accounts Receivable: We estimate losses from the inability of our customers to make required payments and periodically review the payment history of each of our customers, as well as their financial condition, and revise our reserves as a result.

 

RESULTS OF OPERATIONS

 

COMPARISON OF THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011

 

Revenue:  Net revenue decreased to approximately $718,000 for the quarter ended March 31, 2012, from approximately $767,000 for the same period in 2011. Net revenue was lower for the first quarter 2012 due to the timing of the contracts relating to our cancer detection technology.

 

Research and Development Expenses:  Research and development expenses increased to approximately $714,000 for the three months ended March 31, 2012, compared to $696,000 for the same period in 2011.  The increase, of approximately $18,000, was primarily due to an increase in research and development for our cervical cancer detection product, as we prepare for marketing and production.

 

 

 

Sales and Marketing Expenses:  Sales and marketing expenses were approximately $70,000 during the three months ended March 31, 2012, compared to $49,000 for the same period in 2011. The increase was primarily due to efforts underway in marketing our cervical cancer detection product.

 

General and Administrative Expenses:  General and administrative expenses increased to approximately $930,000 during the three months ended March 31, 2012, compared to approximately $762,000 for the same period in 2011.  The increase of approximately $168,000, or 22%, is primarily related to an increase in stock based compensation and material modification associated with our cervical cancer detection product.

 

Net Interest and Other Income:  Other income for the three months ended March 31, 2012 was zero compared to $37,000 in 2011. In the three months ended March 31, 2012, we had approximately $30,000 in reimbursed expenses from Konica Minolta related to an expatriate Konica Minolta employee, which was recorded as other income. Interest expense decreased to approximately $17,000 for the three months ended March 31, 2012, as compared to approximately $23,000 for the same period in 2011 primarily due to repayment of notes during the quarter ended March 31, 2012.

 

Net loss was approximately $1.0 million during the three months ended March 31, 2012, compared to $726,000 for the same period in 2011, for the reasons outlined above.

 

Net loss attributable to common stockholders was approximately $1.0 million during the three months ended March 31, 2012, compared to a net loss attributable to common stockholder of approximately $726,000 during the three months ended March 31, 2011.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Since our inception, we have raised capital through the private sale of preferred stock and debt securities, public and private sales of common stock, funding from collaborative arrangements, and grants. At March 31, 2012, we had cash of approximately $1.0 million and a negative working capital of approximately $482,000.

 

Our major cash flows in the quarter ended March 31, 2012, consisted of cash out-flows of approximately $1.2 million from operations, including approximately $1.0 million of net loss, cash outflow of $130,000 from investing activities and a net change from financing activities of $124,000, which primarily represents the proceeds received from excise of outstanding warrants and options, offset in part by cash utilized for loan repayment.

 

In March 2011, we extended our existing agreement with Konica Minolta for development of our biophotonic platform specific to the detection of esophageal cancer for an additional year, effective May 1, 2011.  In this agreement, we are providing Konica Minolta with technical, regulatory and clinical development of our biophotonic platform device for esophageal cancer detection.  We received approximately $1.72 million in 2011 from Konica Minolta under this development agreement and expect to receive a total of $2.2 million for the third year of development (May 1, 2012 to April 30, 2013).  While at this time our expectation is that our agreement with Konica Minolta will be extended for an additional year, the contract has yet to be signed and there is no certainty that it will be extended.

 

On November 21, 2011, we completed a private placement of 2,056,436 shares of common stock at a purchase price of $0.84 per share, pursuant to which we raised approximately $1.7 million. For each share of common stock issued, subscribers received warrants exercisable for the purchase of 1/10 of one share of common stock (in the aggregate, 285,186 shares) at an exercise price of $1.05 per share. The warrants have a five-year term.

 

We will be required to raise additional funds through public or private financing, additional collaborative relationships or other arrangements in addition to these sources. We believe our existing and available capital resources will be sufficient to satisfy our funding requirements through the first quarter of 2013. We are evaluating various options to further reduce our cash requirements to operate at a reduced rate, as well as options to raise additional funds, including loans using certain assets as collateral.

 

Substantial capital will be required to develop our products, including completing product testing and clinical trials, obtaining all required U.S. and foreign regulatory approvals and clearances, and commencing and scaling up manufacturing and marketing our products. Any failure to obtain capital would have a material adverse effect on our business, financial condition and results of operations.

 

Our financial statements have been prepared and presented on a basis assuming we will continue as a going concern.  The above factors raise substantial doubt about our ability to continue as a going concern, as more fully discussed in Note 1 to the consolidated financial statements contained herein and in the report of our independent registered public accounting firm accompanying our financial statements contained in our annual report on Form 10-K for the year ended December 31, 2011.

 

 

 

Off-Balance Sheet Arrangements

 

We have no material off-balance sheet arrangements, no special purpose entities, and no activities that include non-exchange-traded contracts accounted for at fair value.

 

ITEM 3.     QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4.   CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

The Company under the supervision and with the participation of management, including the Chief Executive Officer (principal executive officer) and the Chief Financial Officer (principal financial officer), evaluated the effectiveness of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of March 31, 2012. The controls and System currently used by the Company to calculate and record inventory is not operating effectively. Additionally, the Company lacks the resources to properly research and account for complex transactions. The combination of these controls deficiencies have resulted in a material weakness in our internal control over financial reporting.

Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were not effective as of March 31, 2012 to provide reasonable assurance that (1) information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (2) information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

The effectiveness of any system of controls and procedures is subject to certain limitations, and, as a result, there can be no assurance that our controls and procedures will detect all errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be attained.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

PART II - OTHER INFORMATION

 

ITEM 1A.  RISK FACTORS

 

Please refer to Part I, Item 1A, “Risk Factors,” in our annual report on Form 10-K for the year ended December 31, 2011, for information regarding factors that could affect our results of operations, financial condition and liquidity.

 

ITEM 6.  EXHIBITS

 

EXHIBIT INDEX

 

EXHIBITS

 

Exhibit Number	Exhibit Description
3.1	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 of the Company’s report on Form 8-K, filed March 23, 2012).
31	Rule 13a-14(a)/15d-14(a) Certification
32	Section 1350 Certification
101	XBRL

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

GUIDED THERAPEUTICS, INC.
/s/ MARK L. FAUPEL
By:	Mark L. Faupel
	President, Chief Executive Officer and
	Acting Chief Financial Officer
Date:	May 14, 2012